LABP News and Press, Landos Biopharma Inc. From 11/16/21

Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...

Landos Biopharma, Inc. (LABP) Q3 2021 Earnings Conference Call November 15, 2021 8:00 A.M. ET Company Participants Becky Mosig - Director of Administration and Operations Chris Garabedian - Chairman of the Board Tim Mayleben - Interim President and Chief Executive Officer Conference Call Part...

Landos Biopharma (NASDAQ:LABP): Q3 GAAP EPS of -$0.32 beats by $0.11. Cash and equivalents of $102.7M Press Release For further details see: Landos Biopharma EPS beats by $0.11

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal En...

BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial result...

A clinical-stage biopharmaceutical company, Landos Biopharma (NASDAQ:LABP) announces that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and CEO, effective immediately. Tim M. Mayleben, a member of the Board, has been appointed Interim President and CEO. Chris Gar...

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed Chairman of the Board BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP), a clinical-s...

Landos Biopharma (NASDAQ:LABP) announces that the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis (RA). Landos has initiated a Phase 1 trial of LA...

Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class therapeutic candidate for systemic lupus erythematosus and rheumatoid art...

Landos Biopharma (NASDAQ:LABP) has dosed the first subject in a Phase 1 study of LABP-104, a potentially first-in-class oral, small-molecule LANCL2 agonist, for the treatment of systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is the most common type of the autoimmune dis...